| Literature DB >> 23442316 |
Carlos A Alvarez1, Christopher A Clark, Song Zhang, Ethan A Halm, John J Shannon, Carlos E Girod, Lauren Cooper, Ruben Amarasingham.
Abstract
BACKGROUND: Accurate, timely and automated identification of patients at high risk for severe clinical deterioration using readily available clinical information in the electronic medical record (EMR) could inform health systems to target scarce resources and save lives.Entities:
Mesh:
Year: 2013 PMID: 23442316 PMCID: PMC3599266 DOI: 10.1186/1472-6947-13-28
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Cohort characteristics (N=46,974 patient-days)
| Number of Patients: | 3624 | 3792 |
| RED events | 298 (1.3) | 287 (1.2) |
| Age, mean (SD) | 50.5 (14.6) | 51 (14.8) |
| Male, n(%) | 2,062 (56.1) | 2,049 (54) |
| Temperature (°F) | 98.1 (1.6) | 98.3 (1.8) |
| Systolic Blood Pressure (mm Hg) | 139.8 (25.0) | 139.6 (24.6) |
| Respirations per minute | 21 (7.3) | 20.7 (6.5) |
| Pulse per minute | 91.3 (19.0) | 92.1 (18.9) |
| Diastolic Blood Pressure (mm Hg) | 83.8 (15.1) | 83.9 (15.4) |
| SpO2 (%) | 95.6 (5.1) | 95.6 (5.0) |
| Platelets (103 cells/mm3) | 242.3 (125.6) | 237.8 (122.6) |
| Potassium (mEq/L) | 4.0 (0.6) | 4.0 (0.6) |
| Glucose (mg/dL) | 128.6 (76.5) | 127.8 (73.9) |
| Hematocrit (g/dL) | 32.4 (6.8) | 32.4 (6.7) |
| Creatinine (mg/dL) | 2 (2.9) | 1.8 (2.7) |
| White Blood Cell Count (103 cells/mm3) | 8.6 (9.5) | 8.6 (7.3) |
| Total Bilirubin (mg/dL) | 1.5 (4.0) | 1.5 (3.6) |
| Sodium (mEq/L) | 135.8 (4.2) | 135.8 (4.4) |
| Arterial pH | 7.4 (0.1) | 7.4 (0.1) |
| Arterial pCO2 (mm Hg) | 37.5 (13.1) | 38.9 (13.5) |
| AST (U/L) | 95.6 (417.2) | 74.5 (211.0) |
| Anion Gap | 10.6 (3.9) | 10.5 (4.0) |
| Albumin (g/dL) | 3.2 (0.7) | 3.2 (0.7) |
| B-type Natriuretic Peptide (pg/mL) | 7,291.6 (14455.7) | 6,357.2 (13019.8) |
| Thyroid Stimulating Hormone (μIU/mL) | 5.4 (21.6) | 4.4 (27.0) |
| Estimated Glomerular Filtration Rate (mL/min/1.73 m2) | 50.5 (17.7) | 50.7 (17.3) |
| Level of Consciousness | 0.1 (0.4) | 0.1 (0.3) |
| Bilevel positive airway pressure | 122 (0.5) | 178 (0.7) |
| Arterial Blood Gas | 1,436 (6.2) | 1,509 (6.3) |
| Troponin I | 3,725 (16.1) | 3,804 (16.0) |
| Electrocardiogram | 4,996 (21.6) | 5,143 (21.6) |
| Electroencephalogram | 87 (0.4) | 115 (0.5) |
| Telemetry | 1,765 (7.6) | 1,787 (7.5) |
| Stat order # 1 | 1,704 (7.4) | 1,902 (8.0) |
| Stat order # 2 | 2,476 (10.7) | 2,614 (11.0) |
| Institute of Safe Medication Practice High Alert Medication | 9,257 (40.0) | 9,554 (40.1) |
| Systemic Steroids | 758 (3.3) | 808 (3.4) |
| Sodium Bicarbonate | 423 (1.8) | 427 (1.8) |
| Lactulose or Rifaxamin | 535 (2.3) | 634 (2.7) |
| Antidote medication | 308 (1.3) | 341 (1.4) |
| More than one nephrotoxic agent taken concurrently | 3,580 (15.5) | 3,502 (14.7) |
| More than one antibiotic agent taken concurrently | 2,549 (11.0) | 2,611 (11.0) |
| Intravenous fluid bolus | 1,270 (5.5) | 1,329 (5.6) |
| Stat acute coronary syndrome medications | 2,436 (10.5) | 2,276 (9.5) |
| Stat seizure abatement medications | 1,069 (4.6) | 1,234 (5.2) |
| MEWS, mean (SD) | 2.2 (1.5) | 2.2 (1.5) |
| High Risk Floor Assignment, n(%) | 2,369 (10.2) | 2,348 (9.9) |
a Resuscitation events and death; b Stat orders for head magnetic resonance imaging or computed tomography scan, chest plain film x-rays or computed tomography scan, and abdominal ultrasonography; c Stat orders for complete blood count, bilevel positive airway pressure, arterial blood gas, troponin, electroencephalogram and electrocardiogram; d antithrombotic agents, chemotherapeutic agents, epidural or intrathecal route of administration, hypoglycemic, magnesium sulfate injection, hypertonic sodium chloride, colchicine injection, and methotrexate oral; e IV or oral prednisone, methylprednisolone, prednisolone, fludricortisone and hydrocortisone; f Protamine, naloxone, phytonadione, flumazenil; g Systemic amphotericin B (lipid and conventional), systemic aminoglycosides, scheduled daily non-steroidal anti-inflammatories, IV vancomycin, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, cyclosporine, tacrolimus, loop diuretics, penicillin antibiotics, acyclovir; h Any aminoglycoside, penicillin, cephalosporin, vancomycin, sulfa antibiotic, linezolid, doxycycline, tigecycline, fluoroquinolone, aztreonam, carbapenem, daptomycin, and nitrofurantoin; i IV metoprolol, sublingual or IV nitroglycerin and aspirin given concurrently; j intramuscular lorazepam or diazepam, phenobarbital, fosphenytoin, and phenytoin; k elements consists of systolic blood pressure, heart rate, respiratory rate, temperature, and level of consciousness; l includes floors that comprise the top 15% of events.
Univariate predictors of RED events (N= 23,127 patient days)
| RED events | 298 (1.3) | | | |
| age > 54 | 9,217 (39.9) | 145 (1.6) | 1.4 (1.14 - 1.81) | 0.002 |
| Temperature (°F) | ||||
| ≤99.5 (ref.) | 20,157 (87.2) | 229 (1.1) | -- | -- |
| >99.5 | 2,970 (12.8) | 69 (2.3) | 2.1 (1.58 - 2.72) | <0.001 |
| Systolic Blood Pressure (mm Hg) | ||||
| ≤125 (ref.) | 7,122 (30.8) | 77 (1.1) | -- | -- |
| >125 | 16,005 (69.2) | 221 (1.4) | 1.3 (0.99 - 1.66) | 0.063 |
| Respirations per minute | ||||
| ≤24 (ref.) | 21,713 (93.9) | 192 (0.9) | -- | -- |
| >24 | 1,414 (6.1) | 106 (7.5) | 9.1 (7.12 - 11.59) | <0.001 |
| Pulse per minute | ||||
| ≤134 (ref.) | 22,464 (97.1) | 240 (1.1) | -- | -- |
| >134 | 663 (2.9) | 58 (8.8) | 8.9 (6.59 - 11.96) | <0.001 |
| Diastolic Blood Pressure (mm Hg) | ||||
| ≤120 (ref.) | 22,507 (97.3) | 265 (1.2) | -- | -- |
| >120 | 620 (2.7) | 33 (5.3) | 4.7 (3.26 - 6.84) | <0.001 |
| spO2 (%) | ||||
| ≤86 | 319 (1.4) | 25 (7.8) | 7.0 (4.59 - 10.74) | <0.001 |
| >86 (ref.) | 22,808 (98.6) | 273 (1.2) | -- | -- |
| Platelets (103 cells/mm3) | ||||
| <100 | 1959 (8.5) | 32 (1.6) | 1.3 (0.90 - 1.89) | 0.158 |
| ≥100 (ref.) | 21,168 (91.5) | 266 (1.3) | -- | -- |
| Potassium (mEq/L) | ||||
| ≤2.9 | 155 (0.7) | 9 (5.8) | 5.4 (2.74 - 10.76) | <0.001 |
| 2.9 - 5.1 (ref.) | 21,811 (94.3) | 245 (1.1) | -- | -- |
| >5.1 | 1,161 (5.0) | 44 (3.8) | 3.5 (2.50 - 4.81) | <0.001 |
| Glucose (mg/dL) | ||||
| ≤250 (ref.) | 22,219 (96.0) | 276 (1.2) | -- | -- |
| 250 – 600 | 825 (3.6) | 17 (2.1) | 1.7 (1.02 - 2.74) | 0.042 |
| >600 | 83 (0.4) | 5 (6.0) | 5.1 (2.05 - 12.69) | <0.001 |
| Hematocrit (g/dL) | ||||
| ≤48 (ref.) | 22,925 (99.1) | 288 (1.3) | -- | -- |
| > 48 | 202 (0.9) | 10 (5.0) | 4.1 (2.15 - 7.81) | <0.001 |
| Creatinine | ||||
| ≤1.5 (ref.) | 17,937 (77.6) | 201 (1.1) | -- | -- |
| >1.5 | 5,190 (22.4) | 97 (1.9) | 1.7 (1.32 - 2.15) | <0.001 |
| White Blood Cell Count (103 cells/mm3) | ||||
| ≤11 (ref.) | 19,225 (83.1) | 204 (1.1) | -- | -- |
| >11 | 3,902 (16.9) | 94 (2.4) | 2.3 (1.80 - 2.95) | <0.001 |
| Total Bilirubin (mg/dL) | ||||
| ≤1.7 (ref.) | 22,172 (95.9) | 271 (1.2) | -- | -- |
| >1.7 | 955 (4.1) | 27 (2.8) | 2.4 (1.57 - 3.51) | <0.001 |
| Sodium (mEq/L) | ||||
| ≤128 | 983 (4.2) | 29 (3.0) | 2.5 (1.69 - 3.69) | <0.001 |
| 128 - 143 (ref.) | 21,808 (94.3) | 262 (1.2) | -- | -- |
| >143 | 336 (1.5) | 7 (2.1) | 1.7 (0.82 - 3.74) | 0.148 |
| pH | ||||
| ≤7.22 | 53 (0.2) | 11 (20.8) | 20.8 (10.60 - 40.80) | <0.001 |
| >7.22 (ref.) | 23,074 (99.8) | 287 (1.2) | -- | -- |
| pCO2 (mm Hg) | ||||
| ≤22 | 78 (0.3) | 12 (15.4) | 14.8 (7.89 - 27.62) | <0.001 |
| 22 - 70 (ref.) | 23,020 (99.5) | 280 (1.2) | -- | -- |
| >70 | 29 (0.2) | 6 (20.7) | 21.2 (8.56 - 52.43) | <0.001 |
| AST (U/L) | ||||
| ≤250 (ref.) | 22,826 (98.7) | 279 (1.2) | -- | -- |
| >250 | 301 (1.3) | 19 (6.3) | 5.4 (3.37 - 8.79) | <0.001 |
| Anion Gap | | | | |
| ≤16 (ref.) | 21,791 (94.2) | 236 (1.1) | -- | -- |
| >16 | 1,336 (5.8) | 62 (4.6) | 4.4 (3.34 - 5.91) | <0.001 |
| Albumin (g/dL) | ||||
| < 3.5 | 2,779 (12.0) | 54 (1.9) | 1.6 (1.21 - 2.20) | 0.001 |
| ≥3.5 (ref.) | 20,348 (88.0) | 244 (1.2) | -- | -- |
| B-type natriuretic peptide (pg/mL) | ||||
| ≤100 (ref.) | 21,803 (94.3) | 257 (1.2) | -- | -- |
| >100 | 1,324 (5.7) | 41 (3.1) | 2.7 (1.92 - 3.74) | <0.001 |
| Thyroid Stimulating Hormone (μIU/mL) | ||||
| ≤0.4 | 60 (0.3) | 3 (5.0) | 4.1 (1.27 - 13.10) | 0.018 |
| 0.4 - 5.4 | 610 (2.6) | 7 (1.2) | 0.9 (0.42 - 1.91) | 0.784 |
| >5.4 | 83 (0.4) | 3 (3.6) | 2.9 (0.91 - 9.26) | 0.071 |
| Not measured (ref.) | 22,374 (96.7) | 285 (1.3) | -- | -- |
| Estimated glomerular filtration rate (mL/min/1.73 m2) | ||||
| ≤30 | 3,009 (13.0) | 57 (1.9) | 1.6 (1.19 - 2.13) | 0.002 |
| >30 (ref.) | 20,118 (87.0) | 241 (1.2) | -- | -- |
| Bilevel positive airway pressure | 122 (0.5) | 11 (9.0) | 7.8 (4.18 - 14.73) | <0.001 |
| Arterial Blood Gas | 1,436 (6.2) | 104 (7.2) | 8.7 (6.77 - 11.05) | <0.001 |
| Troponin I | 3,725 (16.1) | 130 (3.5) | 4.1 (3.28 - 5.22) | <0.001 |
| Electrocardiogram | 4,996 (21.6) | 183 (3.7) | 6.0 (4.71 - 7.54) | <0.001 |
| Electroencephalogram | 87 (0.4) | 1 (1.2) | 0.9 (0.12 - 6.41) | 0.908 |
| Telemetry | 1,765 (7.6) | 36 (2.0) | 1.7 (1.18 - 2.38) | 0.004 |
| Stat order # 1 | 1,704 (7.4) | 45 (2.6) | 2.3 (1.65 - 3.13) | <0.001 |
| Stat order # 2 | 2,476 (10.7) | 70 (2.8) | 2.6 (1.99 - 3.42) | <0.001 |
| Institute of Safe Medication Practice High Alert Medication | 9,257 (40.0) | 162 (1.8) | 1.8 (1.43 - 2.26) | <0.001 |
| Systemic Steroids | 758 (3.3) | 13 (1.7) | 1.4 (0.77 - 2.37) | 0.292 |
| Sodium Bicarbonate | 423 (1.8) | 16 (3.8) | 3.1 (1.87 - 5.22) | <0.001 |
| Lactulose or Rifaxamin | 535 (2.3) | 12 (2.2) | 1.8 (1.00 - 3.21) | 0.051 |
| Antidote medication | 308 (1.3) | 14 (4.6) | 3.8 (2.18 - 6.54) | <0.001 |
| More than one nephrotoxic agent taken concurrently | 3,580 (15.5) | 60 (1.7) | 1.4 (1.04 - 1.84) | 0.026 |
| More than one antibiotic agent taken concurrently | 2,549 (45.3) | 46 (1.8) | 1.5 (1.08 - 2.04) | 0.015 |
| Intravenous fluid bolus | 1,270 (5.5) | 55 (4.3) | 4.0 (2.99 - 5.43) | <0.001 |
| Stat acute coronary syndrome medications | 2,436 (10.5) | 43 (1.8) | 1.4 (1.04 - 1.99) | 0.028 |
| Stat seizure abatement medications | 1,069 (4.6) | 31 (2.9) | 2.4 (1.67 - 3.55) | <0.001 |
| MEWS, Mean (SD) | 2.28 (1.5) | | 1.6 (1.54 - 1.70) | <0.001 |
| Level of Consciousness | | | | |
| 0 – Alert | 7,580 (32.8) | 156 (2.1) | 3.1 (2.41 - 4.00) | <0.001 |
| 1 – Responds to voice/new confusion/restlessness | 543 (2.3) | 23 (4.2) | 6.5 (4.12 - 10.37) | <0.001 |
| 2 – Responds to pain | 102 (0.4) | 6 (5.9) | 9.2 (3.95 - 21.55) | <0.001 |
| 3 – Unresponsive | 32 (0.1) | 13 (40.6) | 101.1 (48.59 - 210.20) | <0.001 |
| Not measured (ref.) | 14,870 (64.3) | 100 (0.7) | -- | -- |
| High Risk Floor Assignment, N(%) | 2,369 (10.2) | 158 (6.7) | 10.5 (8.35 - 13.27) | <0.001 |
a Resuscitation events and death; b Stat orders for head magnetic resonance imaging or computed tomography scan, chest plain film x-rays or computed tomography scan, and abdominal ultrasonography; c Stat orders for complete blood count, bilevel positive airway pressure, arterial blood gas, troponin, electroencephalogram and electrocardiogram; d antithrombotic agents, chemotherapeutic agents, epidural or intrathecal route of administration, hypoglycemic, magnesium sulfate injection, hypertonic sodium chloride, colchicine injection, and methotrexate oral; e IV or oral prednisone, methylprednisolone, prednisolone, fludricortisone and hydrocortisone; f Protamine, naloxone, phytonadione, flumazenil; g Systemic amphotericin B (lipid and conventional), systemic aminoglycosides, scheduled daily non-steroidal anti-inflammatories, IV vancomycin, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, cyclosporine, tacrolimus, loop diuretics, penicillin antibiotics, acyclovir; h Any aminoglycoside, penicillin, cephalosporin, vancomycin, sulfa antibiotic, linezolid, doxycycline, tigecycline, fluoroquinolone, aztreonam, carbapenem, daptomycin, and nitrofurantoin; i IV metoprolol, sublingual or IV nitroglycerin and aspirin given concurrently; j intramuscular lorazepam or diazepam, phenobarbital, fosphenytoin, and phenytoin; k elements consists of systolic blood pressure, heart rate, respiratory rate, temperature, and level of consciousness; l includes floors that comprise the top 15% of events.
Multivariate predictors of RED events (derivation cohort, N= 23,127)
| Age >54 years | 1.59 (1.24 - 2.04) | <0.001 |
| SpO2 (%) (min) ≤86 | 1.73 (1.04 - 2.88) | 0.03 |
| Diastolic BP (mm Hg) (max) >120 | 3.17 (1.16 - 8.66) | 0.03 |
| AST (U/L) (min) >250 | 2.89 (1.62 - 5.17) | <0.001 |
| pCO2 (mm Hg) (max) ≤22 | 3.72 (1.64 - 8.40) | 0.002 |
| pCO2 (mm Hg) (max) >70 | 4.61 (1.84 - 11.56) | 0.001 |
| WBC (103 cells/mm3) (min) >11 | 1.36 (1.03 - 1.79) | 0.03 |
| Platelets (103 cells/mm3) (min) <100 | 1.76 (1.18 - 2.64) | 0.01 |
| Potassium (mEq/dL) (max) >5.1 | 1.77 (1.22 - 2.56) | 0.003 |
| Arterial Blood Gas | 2.08 (1.52 - 2.85) | <0.001 |
| Electrocardiogram | 2.05 (1.54 - 2.73) | <0.001 |
| Stat Physician Order | 2.20 (1.53 - 3.16) | <0.001 |
| High Risk Floor Assignment | 5.71 (4.34 - 7.51) | <0.001 |
| MEWS | 1.36 (1.28 - 1.44) | <0.001 |
| | | |
a Stat orders for head magnetic resonance imaging or computed tomography scan, chest plain film x-rays or computed tomography scan, and abdominal ultrasonography; b includes floors that comprise the top 15% of events; c elements consists of systolic blood pressure, heart rate, respiratory rate, temperature, and level of consciousness.
Figure 1Observed rates of RED events stratified by quintiles of risk in the automated model. Legend: Group 1 is the lowest quintile of risk and group 5 is the highest quintile of risk. The Figure shows comparable performance in the derivation (white bars) and validation (black bars) samples.
Figure 2Comparing Receiver Operator Characteristic curve performance for final automated model versus the MEWS.